Search Results
Your search for 3 matches 14940 pages
Showing 5701 - 5750Cisplatin/Fluorouracil vs Carboplatin/Paclitaxel in Chemotherapy-Naive Patients With Advanced Anal Cancer
In an International Rare Cancers Initiative phase II trial (InterAAct) reported in the Journal of Clinical Oncology, Rao et al found that carboplatin/paclitaxel was associated with less serious toxicity and a trend toward improved overall survival vs cisplatin/fluorouracil in chemotherapy-naive...
Suresh S. Ramalingam, MD, on NSCLC: Nivolumab Plus Ipilimumab vs Chemotherapy
Suresh S. Ramalingam, MD, of Emory University, discusses a 3-year update from the CheckMate 227, Part 1, trial, which showed that nivolumab plus ipilimumab continued to provide durable and long-term overall survival benefit vs platinum-doublet chemotherapy as first-line treatment for patients with...
Percutaneous Cryoablation vs Partial or Radical Nephrectomy for Early-Stage Kidney Cancer
A minimally invasive procedure that destroys cancer cells by freezing them may be an option other than surgery for treating early-stage kidney cancer. The two methods showed similar 10-year survival rates, with cryoablation showing a lower rate of complications, according to a study published by...
Tafasitamab Plus Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
In the phase II L-MIND trial reported in The Lancet Oncology, Gilles Salles, MD, and colleagues found that the combination of the Fc-enhanced anti-CD19 monoclonal antibody tafasitamab plus lenalidomide produced responses in patients with relapsed or refractory diffuse large B-cell lymphoma...
Ripretinib in Previously Treated Patients With Advanced GIST: INVICTUS Trial
As reported in The Lancet Oncology by Jean-Yves Blay, MD, and colleagues, the phase III INVICTUS trial has shown that the oral KIT and PDGFRα tyrosine kinase inhibitor ripretinib prolonged progression-free survival vs placebo in patients with advanced gastrointestinal stromal tumors (GIST) whose...
FDA Approves Pembrolizumab for Adults and Children With Tumor Mutational Burden–High Solid Tumors
On June 16, the U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab (Keytruda) for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden–high (TMB-H; ≥ 10 mutations/megabase [mut/Mb]) solid tumors, as determined by an ...
Stereotactic Ablative Radiotherapy for Oligometastatic Cancer: Long-Term Findings From the SABR-COMET Trial
In a long-term follow-up of the phase II SABR-COMET trial reported in the Journal of Clinical Oncology, David A. Palma, MD, PhD, and colleagues found that the addition of stereotactic ablative radiotherapy (SABR) to palliative standard-of-care treatment in patients with oligometastatic cancers...
First-Line Osimertinib/Bevacizumab for Metastatic EGFR-Mutant Lung Cancer
In the phase II portion of a single-center phase I/II trial reported in JAMA Oncology, Yu et al found that the combination of first-line osimertinib and bevacizumab resulted in a high rate of 1-year progression-free survival in patients with metastatic EGFR-mutant lung cancer. As stated by the...
FDA Extends Indication of Gemtuzumab Ozogamicin for Pediatric Patients With CD33-Positive AML
On June 16, the U.S. Food and Drug Administration (FDA) extended the indication of gemtuzumab ozogamicin (Mylotarg) for newly diagnosed CD33-positive acute myeloid leukemia (AML) to include pediatric patients aged 1 month and older. AAML0531 Efficacy and safety in the pediatric population were...
Early Data Suggest Activity for Oral Selective Estrogen Receptor Degrader in Combination Regimen
The availability of an oral selective estrogen receptor degrader (SERD) would be good news for patients and clinicians as an alternative to intramuscular fulvestrant. The novel agent LSZ102 might fit the bill, based on early activity shown in combination with the targeted agents ribociclib and...
EHA25 Virtual: Roundup of Findings in Leukemia, Lymphoma, and More
Advances in the treatment of hematologic malignancies and some of their associated symptoms were presented during EHA25 Virtual, an ongoing online conference from the European Hematology Association (EHA). Advances in the Treatment of High-Risk CLL: CLL2-GIVe Results In the CLL2-GIVe trial, the...
Immune Checkpoint Inhibitor Rechallenge in Metastatic Renal Cell Carcinoma
In a study presented at the ASCO20 Virtual Scientific Program (Abstract 5077) and published as a brief report in JAMA Oncology, Ravi et al found that rechallenge with immune checkpoint inhibitor therapy was capable of producing responses in patients with metastatic renal cell carcinoma, including...
FGFR1–3 Inhibitor AZD4547 in Refractory Tumors Harboring FGFR Activating Mutations and Fusions
As reported in the Journal of Clinical Oncology by Chae et al, findings in a cohort of the phase II NCI-MATCH trial (EAY131, Subprotocol W) indicated that the oral inhibitor of fibroblast growth factor receptor 1, 2, and 3 (FGFR1–3), AZD4547, produced a small number of responses in patients with a...
Acalabrutinib vs Idelalisib/Rituximab or Bendamustine/Rituximab for Relapsed or Refractory CLL: ASCEND Trial
As reported in the Journal of Clinical Oncology by Ghia et al, the phase III ASCEND trial has shown prolonged progression-free survival with acalabrutinib monotherapy vs investigator’s choice of idelalisib plus rituximab or bendamustine plus rituximab in adult patients with relapsed or refractory...
Expert Point of View: Julia R. White, MD
Julia R. White, MD, Professor of Radiation Oncology at The Ohio State University, Columbus, and the invited discussant of E2108, put these findings into context with three important studies evaluating the benefit of locoregional therapy for de novo stage IV breast cancer: the study from Tata...
Study Finds No Survival Benefit From Local Therapy for de Novo Metastatic Breast Cancer
Women presenting with newly diagnosed de novo metastatic breast cancer derived no additional survival benefit from surgery and radiotherapy given after systemic treatment, although the practice may reduce locoregional progression of disease, according to the results of the phase III E2108 study...
Factors Associated With All-Cause 30-Day Mortality in Patients With Cancer Infected With COVID-19: CCC19 Database Analysis
As reported in The Lancet by Jeremy L. Warner, MD, and colleagues, a cohort study using the COVID-19 and Cancer Consortium (CCC19) database has shown that increased risk of all-cause mortality in patients with cancer infected with COVID-19 is associated with such factors as increased age, male sex, ...
Addition of Pemetrexed vs Vinorelbine to Adjuvant Cisplatin for Nonsquamous NSCLC
In the Japanese phase III JIPANG trial reported in the Journal of Clinical Oncology, Kenmotsu et al found that adjuvant therapy with pemetrexed/cisplatin did not result in superior recurrence-free survival but was better tolerated than vinorelbine/cisplatin in patients with completely resected...
Pembrolizumab Plus Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
In a phase Ib study reported in the Journal of Clinical Oncology, Powell et al found that the addition of pembrolizumab to curative chemoradiotherapy was safe and associated with response in patients with locally advanced head and neck squamous cell carcinoma. Study Details The U.S. multicenter...
Carfilzomib Triplet Fails to Improve Outcomes vs Standard Bortezomib-Based Regimen in Newly Diagnosed Myeloma
For newly treated patients with standard- and intermediate-risk multiple myeloma who are not slated for immediate autologous stem cell transplantation (ASCT), the triplet regimen of carfilzomib/lenalidomide/dexamethasone (KRd) failed to improve progression-free survival vs the current...
Meta-analysis of Outcomes With Checkpoint Inhibitor Treatment in Advanced Microsatellite Instability–High Cancers
A meta-analysis of published studies of immune checkpoint inhibition for advanced microsatellite instability–high (MSI-H) cancers—published as a brief report in JAMA Oncology by Petrelli et al—found high activity of these therapies across tumor types and evaluated agents. Study Details The...
Real-World Outcomes With Axicabtagene Ciloleucel Therapy in Relapsed or Refractory Large B-Cell Lymphoma
In a retrospective study reported by Nastoupil et al in the Journal of Clinical Oncology, researchers in the U.S. Lymphoma CAR T Consortium described outcomes with standard-of-care use of the autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel in patients ...
FDA Approves Nivolumab for Pretreated Patients With Esophageal Squamous Cell Carcinoma
On June 10, the U.S. Food and Drug Administration (FDA) approved nivolumab (Opdivo) for patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based chemotherapy. ATTRACTION-3 Efficacy was investigated in...
Breastfeeding: A Public Health Strategy for Reducing Risk of Ovarian Cancer
Although early-stage disease is highly curable, most ovarian cancers are diagnosed at later stages due to a lack of effective screening. As a result, less than 50% of women survive beyond 5 years. Improving prevention by identifying modifiable risk factors could dramatically change the outcome of...
Breastfeeding Associated With Reduced Risk of Invasive Ovarian Cancer, Including High-Grade Serous Disease
In a pooled analysis reported in JAMA Oncology,1 Naoko Sasamoto, MD, MPH, of the Obstetrics and Gynecology Epidemiology Center, Brigham and Women’s Hospital, Boston, and colleagues found that breastfeeding, even for durations of 1 to 3 months per birth, was associated with a significant reduction...
Veliparib Plus Chemotherapy Shows Antitumor Activity in Front-Line Treatment of Ovarian Cancer, but Is It Enough?
An updated analysis of the phase III VELIA/GOG-3005 trial, presented during the 2020 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer Webinar Series,1 suggested synergy between the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib and platinum chemotherapy in the...
Niraparib for First-Line Maintenance Treatment of Advanced Ovarian Cancer
On April 29, 2020, niraparib was approved for maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.1,2 Supporting Efficacy Data Approval was based on...
Front-Line Maintenance With Olaparib/Bevacizumab Improves Outcomes in Advanced Ovarian Cancer
Proponents of combining bevacizumab with poly (ADP-ribose) polymerase (PARP) inhibition to treat advanced ovarian cancer now have more data to support the maintenance regimen, according to an updated analysis of the phase III PAOLA-1 trial presented during the 2020 Society of Gynecologic Oncology...
KEYNOTE-555 Supports 6-Week Pembrolizumab Dosing Schedule in Melanoma
A less-frequent, more-convenient dosing schedule for pembrolizumab (400 mg every 6 weeks) was deemed safe and effective in patients with unresectable or metastatic melanoma, according to interim data from cohort B enrolled in the KEYNOTE-555 trial. These findings were presented at the 2020 Virtual...
Talazoparib Yields No Overall Survival Benefit in EMBRACA Trial Update
The poly (ADP-ribose) polymerase inhibitor talazoparib did not improve overall survival in women with metastatic HER2-negative breast cancer and mutations in the BRCA1 and BRCA2 genes, according to new results from the phase III EMBRACA trial presented at the 2020 American Association for Cancer...
Study Finds Blood Test Detects Cancer and Tissue of Origin in Those With or Suspected to Have Cancer
A blood test based on cell-free DNA was able to detect cancer as well as the site of origin in patients with a clinical suspicion of cancer, according to results of the Circulating Cell-Free Genome Atlas (CCGA) study presented at the 2020 American Association for Cancer Research (AACR) Virtual...
Expert Point of View: Yvonne Chen, PhD, and Joseph Alvarnas, MD
Formal discussant Yvonne Chen, PhD, Associate Professor of Microbiology, Immunology, and Molecular Genetics at the University of California, Los Angeles, said the issue of toxicity was important, since high levels of toxicity were observed in this small group of five patients. “All five patients...
Off-the-Shelf CAR T-Cell Therapy Makes Inroads in Acute Lymphoblastic Leukemia
Chimeric antigen receptor (CAR) T-cell therapy known as TruUCAR GC027 may prove to be useful in the treatment of adult patients with relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) and potentially other hematologic malignancies. Preliminary results in a small number of patients...
When Is It Time to Pass?
Assisted suicide gets a lot of press, as if it were a new event. About 20 to 30 years ago, it was ever present but neither defined nor acknowledged. When patients left the hospital for what they and I believed to be the last time, I did one or both of two things: gave them my home number or, if...
My Future Is Doled Out in Increments of 6 Months
In the fall of 2015, I was looking forward to a trip to Florida for a visit with my daughter and her family, along with a little relaxation. The evening before the trip, I experienced some abdominal pain that my wife, Angela, and I thought might be appendicitis. Concerned the problem could...
Cognitive Impairment in Women Treated for Early Breast Cancer: Chemoendocrine Adjuvant Therapy vs Endocrine Therapy Alone
Women with early-stage breast cancer who received adjuvant chemoendocrine therapy reported greater cognitive impairment at 3 and 6 months than women receiving adjuvant endocrine therapy alone, according to the results from a subgroup of women participating in the TAILORx trial.1 By 12 months, the...
The Gambler
The ASCO Post is pleased to reproduce installments of Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays, historical...
FDA Approves Combination Regimens in NSCLC, HCC
On May 29, 2020, the U.S. Food and Drug Administration (FDA) approved two combination regimens: ramucirumab (Cyramza) was approved in combination with erlotinib for the first-line treatment of patients with metastatic non–small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)...
Comprehensive Overview of How to Start or Improve a Breast Cancer Unit on the Global Stage
Breast cancer is the leading cause of cancer death among women worldwide. As populations age, the incidence of cancer inevitably increases—the World Health Organization has predicted a dramatic increase in global breast cancer cases during the next 15 years. Moreover, breast cancer is increasing in ...
Selpercatinib for Lung and Thyroid Cancers With RET Gene Mutations or Fusions
On may 8, 2020, selpercatinib was granted accelerated approval for the following indications: Adult patients with metastatic RET fusion-positive non–small cell lung cancer (NSCLC) Adult and pediatric patients ≥ 12 years of age with advanced or metastatic RET-mutant medullary thyroid cancer who...
Ibrutinib in Combination With Rituximab in Chronic Lymphocytic Leukemia
On April 21, 2020, ibrutinib was granted an expanded indication for use in combination with rituximab for the initial treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).1,2 The recommended dosage of ibrutinib in CLL/SLL is 420 mg, once daily,...
Cancer and COVID-19: Considerations About Neutropenia, Anemia, and Thrombocytopenia
GUEST EDITORS Dr. Abutalib is Associate Director of the Hematology and Cellular Therapy Program and Director of the Clinical Apheresis Program at Cancer Treatment Centers of America, Zion, Illinois; Associate Professor at the Roseland Franklin University of Medicine and Science; and Founder and...
In Biochemically Recurrent Prostate Cancer, PSMA-Targeted PET/CT Imaging May Be Useful
Positron-emission tomography/computed tomography (PET/CT) imaging with the prostate-specific membrane antigen (PSMA)-targeted radiotracer fluorine F-18 DCFPyL (PyL) successfully identified areas of occult metastasis in men with biochemically recurrent metastatic castration-resistant prostate...
Olaparib Plus Bevacizumab in Maintenance Treatment for Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
On May 8, 2020, olaparib was granted an expanded indication to include use in combination with bevacizumab for first-line maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line...
Safety and Patient-Reported Outcomes From the IMpower150 Trial in Metastatic Nonsquamous NSCLC
A safety and patient-reported outcome analysis from the IMpower150 trial, reported in the Journal of Clinical Oncology by Martin Reck, PhD, and colleagues, indicated that atezolizumab plus bevacizumab and chemotherapy appeared to be a manageable and tolerable regimen when compared with atezolizumab ...
Outcomes With Minimally Invasive vs Open Esophagectomy in Routine Practice
In a Dutch study reported in the Journal of Clinical Oncology, Markar et al found that routine use of minimally invasive vs open esophagectomy for esophageal cancer was associated with increased risk of pulmonary complications and other adverse outcomes, contrary to the findings of the clinical...
Sacituzumab Govitecan-hziy for Previously Treated Metastatic Triple-Negative Breast Cancer
On April 22, 2020, the antibody-drug conjugate sacituzumab govitecan-hziy was granted accelerated approval for treatment of adult patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease.1,2 Supporting Efficacy Data Approval was...
IMbassador250 Trial: No Survival Benefit With Atezolizumab and Enzalutamide in Metastatic Prostate Cancer
The addition of the checkpoint inhibitor atezolizumab to enzalutamide failed to improve overall survival compared with enzalutamide alone in men with metastatic castration-resistant prostate cancer in the phase III IMbassador250 trial, according to results presented at the 2020 American Association ...
PSA Level Prior to Salvage Radiotherapy: Tailoring Delivery of ADT to Men With Prostate Cancer Most Likely to Benefit
In a recent article in JAMA Oncology, reviewed in this issue of The ASCO Post, Dess et al present an important analysis to help guide decision-making in the setting of salvage radiotherapy in prostate cancer.1 This secondary analysis assessed the association of prostate-specific antigen (PSA)...
Presalvage Radiotherapy PSA Levels and Outcomes With Long-Term Antiandrogen Therapy in Prostate Cancer
In an analysis from the NRG/RTOG 9601 trial reported in JAMA Oncology,1Robert T. Dess, MD, of the Department of Radiation Oncology, University of Michigan, Ann Arbor, and colleagues found that men with higher prostate-specific antigen (PSA) presalvage radiotherapy levels after prostatectomy had a...
